“OKYO Pharma Limited: A Pioneer in the Pharmaceutical Industry”
In today’s fast-paced world, the field of pharmaceuticals is constantly evolving to meet the growing demand for innovative and effective healthcare solutions. Among the many companies striving to make a difference in this industry, OKYO Pharma Limited stands out as a pioneer and leader. This article will delve into the history, achievements, and future prospects […]
Unveiling Alchemist Mining (CSE:AMS) Revolutionizing Mining
Alchemist Mining (CSE:AMS) stands as a pioneering force in the mining industry, committed to revolutionizing traditional mining practices through advanced technologies and sustainable solutions. This article delves into the intriguing world of Alchemist Mining, shedding light on the company’s mission, achievements, and its dedicated team of employees.
Why CytRx Corporation (NASDAQ:CYTR) Stock Could Keep Dropping
CytRx Corporation (NASDAQ:CYTR) shares were down 15.02% on Thursday to $0.685 and an additional 7.65% in after-hours trading to $0.632. The company has a market cap of $75.70 million at 117.32 million shares outstanding. Share prices have been trading in a 52-week range of $0.36 to $3.46.
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. It is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.
The company is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
Earlier this month, CytRx Corporation announced that an abstract describing results from its global Phase 3 clinical trial evaluating aldoxorubicin versus investigators’ choice in patients with relapsed and refractory soft tissue sarcomashas been selected for an oral presentation at the 2017 American Society of Clinical Oncology in June.
We look forward to presenting the more detailed and updated global Phase 3 results to the medical community at ASCO this year,” said Daniel Levitt, M.D., Ph.D., Chief Operating Officer and Chief Medical Officer of CytRx Corporation. “The Phase 3 trial and the combination trial of aldoxorubicin with ifosfamide continue to build on our prior studies showing the utility of aldoxorubicin as a treatment for patients with STS. These trials, together with our other clinical and pre-clinical studies of aldoxorubicin, will support our planned New Drug Application submission.”
However, the gains were quickly faded when CytRx Corporation recently announced a proposed public offering of its common stock that is subject to market conditions. The company plans to use the proceeds for working capital and general corporate purposes, including clinical and regulatory activities, new drug discovery activities, and possible future strategic transactions.
Also, there an be no assurance as to whether or when the offering may be consummated, or as to the actual size or terms of the offering. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
Why NanoViricides Inc (NYSEMKT:NNVC) Shares Could Recover Soon
NanoViricides Inc (NYSEMKT:NNVC) shares dipped 2.61% on Wednesday to $1.12 and were unchanged in after-hours trading. Share prices have been trading in a 52-week range of $1.03 to $2.18. The company has a market cap of $72.89 million at 62.82 million shares outstanding.
NanoViricides Inc is a nano-biopharmaceutical company with several drugs in various stages of development. The company focuses on its research and clinical programs on specific anti-viral therapeutics. It is engaged in the application of nanomedicine technologies to the issues of viral diseases.
Its nanoviricide technology enables direct attacks at multiple points on a virus particle. In addition, the nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients within the core of the nanoviricide. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.
In a press release, NanoViricides Inc shared that Eugene Seymour, MD, MPH, CEO, will present information about the company and its progress towards human trials at the Planet Microcap conference at the Planet Hollywood Hotel later today. This Planet MicroCap Showcase brings together the most promising companies and the top dealmakers in MicroCap Finance for three days of company presentations, one-on-one meetings, and networking.
The company has previously reported that its broad spectrum anti-herpesvirus drug candidates were highly effective in treating HSV-1 infection in a lethal animal model. It has since improved on its Herpecide technology, which ncludes development of skin cream/lotion for the treatment of herpes labialis typically caused by HSV-1, genital lesions typically caused by HSV-2, shingles caused by reactivation of the human herpesvirus-3 and eye drops or gel for the treatment of herpes keratitis of the external eye.
In particular, NanoViricides Inc believes that its drug candidate for the topical treatment of shingles would have the fastest drug development path towards human clinical trials. It has also been working on scaling up production of this drug candidate with the goal of developing 500g to 1kg per batch production capability.
Apart from this, the company has eight different drugs in development, including four indications in the HerpeCide program. It is one of a few bio-pharma companies that has all the capabilities needed from research and development to marketable drug manufacture in the small quantities needed for human clinical trials. All the biological testing and characterization of these drug candidates continues to be performed by external academic or institutional collaborators and contract research organizations.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
Why NOHO Inc (OTCMKTS:DRNK) Shares Popped 14% Higher
NOHO Inc (OTCMKTS:DRNK) shares were up 14.29% on Monday to $0.00040 and unchanged in after-hours trading. Share prices have been trading in a 52-week range of $0.00 to $0.00. The company has a market cap of $2.87 million at 656.04 million shares outstanding.
NOHO Inc is a company that develops, markets, sells and distributes a beverage category product named NOHO – The Hangover Defense (NOHO). Its flagship product NOHO is a dietary supplement, which is taken before and after the consumption of alcohol that helps to prevent the symptoms associated with a hangover.
NOHO is formulated by a Doctor of Pharmacy and comes in a 2 ounce shot. It is recommended that the 2 ounce shot be taken before and after drinking any alcoholic beverages. NOHO has a flavor, which contains no caffeine or stimulants. It has also launched NOHO Gold, which is a premium lifestyle beverage that is developed and marketed as a healthy beverage. NOHO Gold is offered to and sold in premier nightclubs On Premise bar and club venues in the United States including the Fontainebleau Hotel, LIV nightclub, Story nightclub, Day Light, Light, The Opium Group properties, and others.
In a press release, NOHO Inc announced that it has reached an agreement in principle with its 95% majority convertible note holder for a moratorium on conversions, relating to notes issued after March 7, 2015. Apart from this, it will also maintain its ability to retire the outstanding notes in cash.
“We have come to terms with our majority note holder to freeze conversions, which puts NOHO in a very strong position moving forward with significant developments underway. This is a strong signal of our majority debt holders confidence in the long term vision we have for the Company. This agreement is also a big win for our shareholders, as we continue to make changes to reduce the outstanding shares and avoid dilution as a priority moving forward,” said NOHO Inc CEO David Mersky.
Under the terms of this agreement, NOHO Inc will be forming a financial services division wherein a percentage of top line revenues will be allocated toward funding the debt repurchase plan. Details have yet to be announced before May 31, 2017. Note that if the notes subject to the freeze are not repurchased by NOHO Inc, there will be a restriction of stock sales, subject to a lockdown and leakout agreement, which is currently being finalized.
Prior to this, NOHO Inc announced the signing of a national sales and distribution agreement with BNG Enterprises, Inc. in Arizona for the exclusive rights to sell the NOHO 2oz Shot in its nationwide retail stores as well as online sales through Amazon.
NOHO is proud to announce this deal with BNG Enterprises and is excited to begin moving product into retail stores across the country. In addition to its core strength in selling to retail smoke shops and vape stores, where NOHO is a natural fit, BNG also has established relationships with big box retailers, convenience stores and the supermarket space. This deal brings NOHO the ability to manufacture, warehouse and ship product through a well-established sales and distribution partner with a stellar reputation. This is just the beginning of what we envision to be a long-term relationship,” noted CEO Mersky.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
March Review Released for INVICTUS MD Strategies Corp (OTCMKTS:IVITF)
INVICTUS MD Strategies Corp (OTCMKTS:IVITF) shares ticked 9.75% higher to $1.27 on Wednesday and were flat in after-hours trading. Share prices have been trading in a 52-week range of $0.18 to $1.61. The company has a market cap of $43.50 million at 37.50 million shares outstanding.
INVICTUS MD Strategies Corp is a company that is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including an investment in a fully licensed facility, AB Laboratories Inc. as well as the option to now acquire 100% of Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.
In a press release, INVICTUS MD Strategies Corp Chairman Dan Kriznic provided a month in review, highlighting the transformational time for the company as it worked to expand and solidify its cultivation portfolio with expansion plan forecasts of 50,000 kilograms of high quality cannabis production by 2020.
He started off by sharing that CBC News learned that marijuana could be legal in Canada by July 1, 2018 and that the legislation will be announced during the week of April 10. Analysts estimate that this industry could reach $22.6 billion over the coming years, according to Deloitte, with a retail market worth up to $8.7 billion. So far, there are only 41 producers licensed by Health Canada so there’s still significant potential for INVICTUS MD Strategies Corp to capitalize on this growth over time.
At the beginning of March, INVICTUS MD Strategies Corp announced that it had closed its previously announced bought deal private placement with Canaccord Genuity Corp. and Eventus Capital Corp., including a portion of the over-allotment option, for aggregate gross proceeds of $16,218,065. Soon after, the company completed its final commitment with a cash transaction of CAD$2,000,000 to acquire 33.33% of AB Laboratories Inc. This is a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations in Ontario.
Towards the end of the month, the company closed the definitive option agreement to acquire 100% interest in OptionCo which had received its license to cultivate under the Access to Cannabis for Medical Purposes Regulations as Acreage Pharms Ltd. It has constructed a 6,800 square foot production facility with an expansion plan floor plate of 30,000 square feet, and the option to add a 20,000 square foot mezzanine on 150 acres of land in Alberta.
As one of the few cannabis producing companies in North America listed on a major exchange such as the TSXV, that move will enable us to engage a wider investor audience,” said Dan Kriznic, Chairman & CEO, Invictus MD. “We are strongly focused on building our shareholder value. With 250 acres of cultivation space that stretches from Alberta to Ontario, allowing for purpose built production facilities rather than retrofitting existing buildings, we now have the largest land package in Canada for building cultivation facilities as demand increases and we will continue the disciplined but agile execution of our business strategy,” added Kriznic.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
Catch Peregrine Pharmaceuticals (NASDAQ:PPHM) Shares on This Pullback
Peregrine Pharmaceuticals (NASDAQ:PPHM) shares dipped 2.60% on Monday to $0.637 and were flat in after-hours trading. Share prices have been trading in a 52-week range of $0.28 to $0.77. The company has a market cap of $184.75 million at 297.71 million shares outstanding.
Peregrine Pharmaceuticals is a biopharmaceutical company that operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.
Bavituximab, which is its lead immunotherapy candidate, is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The company’s subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.
In a press release, Peregrine Pharmaceuticals announced the presentation of positive new data from the company’s ongoing collaboration with researchers from Memorial Sloan Kettering Cancer Center. This will highlight the phosphatidylserine (PS)-targeting antibodies to enhance the anti-tumor activity of adoptive T cell transfer therapy without triggering any off-target toxicities.
While adoptive T cell transfer remains one of the most exciting new approaches to treating cancer, to date the toxicity associated with the treatment has limited its potential. We are encouraged that these study results showed that the combination of anti-PS and adoptive T cell treatment led to enhanced anti-tumor effect without any evidence of additional off-target side effects,” said Taha Merghoub, Ph.D., co-director of the Ludwig Collaborative Laboratory at MSK. “We believe that these findings may support potential applications for this combination in solid tumors in the future.”
Cancer immunotherapy thought-leaders, Taha Merghoub, Ph.D. and Jedd D. Wolchok, M.D., Ph.D., evaluated and compared the anti-tumor activity and off-target toxicities of adoptive T cell transfer therapy in combination with either PS-targeting antibodies. Additional study results demonstrated that the PS-targeting antibodies decreased tumor-induced immunosuppression as evidenced by a decrease in immunosuppressive regulatory T cells (Tregs) and M2 macrophages, consistent with Peregrine Pharmaceuticals belief that bavituximab may modulate the immunosuppressive tumor microenvironment and enhance the activity of immunotherapy agents.
These study results provide further support for our belief that anti-PS agents such as bavituximab can play an important role as part of combination cancer treatments. This is directly tied to the agents’ ability to modulate the tumor microenvironment to combat the immunosuppression that limits the activity of CAR T and immunotherapies,” said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine Pharmaceuticals.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
QS Energy Inc (OTCMKTS:QSEP) Shares Tick Higher on New Appointment
QS Energy Inc (OTCMKTS:QSEP) shares were up 0.14% to $0.0700 on Friday and were unchanged in after-hours trading. Share prices have been trading in a 52-week range of $0.03 to $0.19. The company has a market cap of $13.92 million at 199.05 million shares outstanding.
Formerly Save the World Air Inc, QS Energy Inc develops and commercializes energy efficiency technologies. As such, it provides the energy industry with industrial equipment that are designed to deliver measurable performance improvements to crude oil pipelines.
Its primary technology is called Applied Oil Technology (AOT), a commercial-grade crude oil pipeline transportation flow-assurance product. AOT is used to manage the energy efficiency of oil pipeline pump stations. The AOT product has transitioned from the research and development stage to initial commercial production for the midstream pipeline marketplace. QS Energy Pool, Inc., a subsidiary of the Company, serves as a vehicle for the Company to explore, review and consider acquisition opportunities.
In a press release, QS Energy Inc gave a shareholder update on the appointment of energy industry veteran Jason Lane as CEO and Chairman of the Board. The statement from Greggory M. Bigger, Chief Executive Officer and Chairman of QS Energy started off by saying that the company broadened the range of crude oil it can treat and increased its practical applications within the upstream and midstream sectors and that management believes that they can realize their goal of making a significant contribution to the energy industry’s relentless drive to more efficiently and cost-effectively transport crude oil to market.
To continue in our efforts to maximize the commercial potential of our patented technology and ensure the highest degree of shareholder value moving forward, we are transitioning to a new Chief Executive Officer and Chairman, and a new member of the Board of Directors, as part of our strategic succession plan,” he stated.
After an extensive review of candidates, Bigger announced that Jason Lane will be incoming CEO and Chairman of QS Energy. He has a strong track record in the industry, specifically in the acquisition, leasing and royalty management of oil and gas and mineral rights. He is CEO and founder of JBL Royalty Company, having produced substantial value for investors with his expertise in the areas of capitalization, procurement and management of energy-related partnerships and joint ventures.
I believe that in the months to come under Jason’s guidance and with the continued support of our loyal shareholders, the commercialization of AOT and its potential for widespread adoption throughout the energy industry will be fully explored. I’m personally delighted at this prospect and look forward to, as a fellow shareholder, this potential eventuality. My team and I have had the distinct pleasure in bringing this technology forward from lab to prototype testing in commercial installations. With this succession, I believe Jason Lane will bring additional capital, contacts and other capabilities that should accelerate the development and adoption of our technology portfolio by leading producers and transporters,” Bigger assured.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.